|
Days 3 and 4 ASH Summaries...
The summaries from the Mon. and Tues. presentations and poster sessons is now available on the MDS Beacon. Brief updates together with links to their abstracts from many well-respected researchers. 
__________________
Ric: Low-risk MDS (blasts <4%); 4 cycles Revlimid no positive response; PRBC transfusion dependent; so far, 392'units' over 8 3/4 years; BMB #4 (15/04/01) shows evolution to AML (blasts 20-30%  ) 47,XY,del(5) (q22q35),+21[24][cp24]/46,XY(1).
|